Pathophysiology of inhibitors to factor VIII in patients with haemophilia A

被引：23

作者：

Lacroix-Desmazes, S ^{[1
]}

Misra, N ^{[1
]}

Bayry, J ^{[1
]}

Artaud, C ^{[1
]}

Drayton, B ^{[1
]}

Kaveri, SV ^{[1
]}

Kazatchkine, MD ^{[1
]}

机构：

[1] Hop Broussais, INSERM, U430, F-75014 Paris, France

来源：

HAEMOPHILIA | 2002年 / 8卷 / 03期

关键词：

factor VIII; FVIII inhibitor; haemophilia; idiotype;

D O I：

10.1046/j.1365-2516.2002.00624.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The occurrence of factor VIII (FVIII) inhibitors is one of the major complications of the treatment of haemophilia A. We present this review as a description of the major players of the antiFVIII immune response, with particular emphasis on the nature and properties of the different antiFVIII antibodies, their mechanisms of action in inhibiting FVIII activity, their potential neutralization by anti-idiotypic antibodies, and the importance of the T cell in participating in the induction of FVIII inhibitors. We briefly conclude on the avenues that remain to be explored in order to establish efficient therapeutic approaches aimed at eliminating FVIII inhibitors in patients with haemophilia A.

引用

页码：273 / 279

页数：7

共 50 条

[31] Factor VIII inhibitors in mild and moderate-severity haemophilia A
Hay, CRM
HAEMOPHILIA, 1998, 4 (04) : 558 - 563
[32] Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A
van Helden, P. M. W.
Kaijen, P. H. P.
Mauser-Bunschoten, E. P.
Fischer, K.
van den Berg, H. M.
Voorberg, J.
HAEMOPHILIA, 2010, 16 (06) : 892 - 901
[33] Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review
Miller, C. H.
HAEMOPHILIA, 2018, 24 (02) : 186 - 197
[34] The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A
Lacroix-Desmazes, S
Bayry, J
Misra, N
Kaveri, SV
Kazatchkine, MD
HAEMOPHILIA, 2002, 8 : 55 - 59
[35] Prevalence of factor VIII inhibitors with clinical relevance in haemophilia treatment
Pollman, H
Richter, H
BLOOD, 1996, 88 (10) : 1308 - 1308
[36] Factor VIII inhibitors in mild and moderate-severity haemophilia A
Hay, CRM
Ludlam, CA
Colvin, BT
Hill, FGH
Preston, FE
Wasseem, N
Bagnall, R
Peake, IR
Berntorp, E
Bunschoten, EPM
Fijnvandraat, K
Kasper, CK
White, G
Santagostino, E
THROMBOSIS AND HAEMOSTASIS, 1998, 79 (04) : 762 - 766
[37] FEIBA® in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre
Smejkal, P.
Brabec, P.
Matyskova, M.
Bulikova, A.
Slechtova, M.
Kissova, J.
Chlupova, G.
Muzik, J.
Penka, M.
HAEMOPHILIA, 2009, 15 (03) : 743 - 751
[38] Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products
Rota, Matteo
Cortesi, Paolo A.
Steinitz-Trost, Katharina N.
Reininger, Armin J.
Gringeri, Alessandro
Mantovani, Lorenzo G.
BLOOD COAGULATION & FIBRINOLYSIS, 2017, 28 (08) : 627 - 637
[39] Thrombelastography rotational (ROTEM®) utility for monitoring patients with haemophilia and factor VIII inhibitors treated with FEIBA®
Garcia-Rodriguez, M.
Martin-Salces, M.
Alvarez, M.
Fernandez, I
Butta, N.
Munoz, I
Rivas, I
Jimenez-Yuste, V
Hernandez-Navarro, F.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1135 - 1135
[40] IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A
Peyvandi, Flora
Miri, Syna
Bucciarelli, Paolo
Valsecchi, Carla
Schiavone, Lucia
Boscarino, Marco
Palla, Roberta
Mannucci, Pier Mannuccio
Rosendaal, Frits Richard
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (03) : 621 - 625

← 1 2 3 4 5 →